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Abstract. 
 
The transcription coactivator and histone
acetyltransferase CAMP response element–binding
protein (CBP) has been demonstrated to accumulate in
promyelocytic leukemia (PML) bodies. We show that
this accumulation is cell type speciﬁc. In cells where
CBP does not normally accumulate in PML bodies, it
can be induced to accumulate in PML bodies through
overexpression of either CBP or Pml, but not Sp100.
Using ﬂuorescence recovery after photobleaching, we
demonstrate that CBP moves rapidly into and out of
PML bodies. In contrast, Pml and Sp100 are relatively
immobile in the nucleoplasm and within PML nuclear
bodies. They possess the characteristics expected of
proteins that would play a structural role in the integ-
rity of these subnuclear domains. Our results are consis-
tent with CBP being a dynamic component of PML
bodies and that the steady-state level in these structures
can be modulated by Pml.
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Introduction
 
The cell nucleus is highly organized and contains well-
 
defined subdomains. In contrast to cytoplasmic organelles, the
 
different subnuclear compartments are not separated from
the surrounding by a lipid bilayer. Instead, subnuclear struc-
tures are delineated by an accumulation of specific proteins
within a defined volume and retain a typical size, shape, and
number under normal growth conditions. It is not known
how such compartments are formed, and it remains to be
shown whether an underlying structural framework locally
concentrates the components or whether the local accumu-
lation results from random aggregations of rapidly diffusing
components (Pederson, 2000). Specific proteins have been
shown to associate and dissociate rapidly between the nucle-
oplasm and subnuclear compartments (Kruhlak et al., 2000;
Phair and Misteli, 2000), but how such mobile proteins are
concentrated within these compartments is not known.
The promyelocytic leukemia (PML)
 
1
 
 nuclear body, a nu-
clear matrix–associated structure of 250–500 nm in diame-
ter, is present in the nucleus of most cell lines (Ascoli and
Maul, 1991; Stuurman et al., 1992). The first biochemical
component of PML nuclear bodies to be identified was the
Sp100 nuclear matrix–associated protein, an autoantigen in
some patients with primary biliary cirrhosis (Szostecki et al.,
1990). This protein may transactivate a variety of promoters
(Guldner et al., 1992; Xie et al., 1993). The PML gene prod-
uct, Pml, is also found in PML nuclear bodies and is the only
protein necessary for the formation of PML nuclear bodies
(Ishov et al., 1999). In some forms of acute PML, a t(15:17)
chromosomal translocation creates a fusion protein of Pml
and the retinoic acid receptor 
 
a 
 
(de The et al., 1990, 1991;
Kakizuka et al., 1991) which influences PML body integrity.
Disruption of the PML nuclear bodies, and not the misregu-
lation of the retinoic acid pathway, is the cause of cell trans-
formation (Kogan et al., 2000). Since some components of
the PML nuclear body may not function constitutively, or
may function at multiple sites throughout the nucleoplasm,
it would be predicted that they would be transient occu-
pants of PML nuclear bodies. However, components that
are necessary for the integrity of the domains would be pre-
dicted to be residents of PML nuclear bodies.
 
We have shown that nuclei that have not been exposed to
extraction or other disruptive procedures possess a protein-
based architecture (Hendzel et al., 1999). Surprisingly, such
structures completely devoid of chromatin can be enriched in
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transcription regulatory factors (Hendzel et al., 1998). The
core of the PML nuclear body is an example (Boisvert et al.,
2000). CAMP response element–binding protein (CBP), a
growth suppressor and histone acetyltransferase (Kwok et al.,
1994; Arany et al., 1995; Giordano and Avantaggiati, 1999), is
highly enriched in PML nuclear bodies (LaMorte et al., 1998;
Doucas et al., 1999; Boisvert et al., 2000). Whether PML bod-
ies represent aggregations of randomly diffusing proteins, or
alternatively are established by an underlying protein-based
architecture, remains to be determined. In this study, we
show that some components of the PML body are immobile
and may play a structural role, whereas at least one other
component, CBP, diffuses into and out of the PML body and
accumulates in the PML body under some conditions.
 
Materials and Methods
 
Immunodetection of PML Nuclear Bodies
 
10T1/2, 293, and SK-N-SH cells were cultured directly on glass coverslips
under conditions recommended by the American Type Culture Collection.
 
Cells were fixed with 1.0% paraformaldehyde in PBS (pH 7.5) at room
temperature for 5 min. Subsequently, cells were permeabilized in PBS con-
taining 0.5% Triton X-100 for 5 min. PML protein was visualized using an
anti-PML antibody (5E10; Stuurman et al
 
.
 
, 1992). CBP was labeled using
an anti-CBP NH
 
2
 
-terminal antibody (no. sc-369, Santa Cruz Biotechnol-
ogy, Inc.; or no. 06-297, Upstate Biotechnology). Cells were then labeled
using the following secondary antibodies: goat anti–rabbit-Cy3 (Chemi-
con), goat anti–mouse-Cy5 (Amersham Pharmacia Biotech), and goat
anti–human-FITC (Jackson ImmunoResearch Laboratories). After rins-
ing, the samples were mounted in 1 mg/ml paraphenylenediamine in PBS/
90% glycerol, containing DNA-specific staining DAPI at 1 
 
m
 
g/ml. Digital
deconvolution confocal imaging was performed using a 14-bit cooled CCD
camera (Princeton Instruments) mounted on a Leica DMRE immunofluo-
rescence microscope. VayTek Microtome digital deconvolution software
was used to remove out-of-focus contributions, and image stacks were pro-
jected into one image plane using Scion Image software. False coloring
and superimposition was done with Adobe Photoshop
 
®
 
 5.0.
 
DNA Constructs and Transient Transfection
 
The CBP protein (a gift from Dr. X.J. Yang, McGill University, Montreal,
Quebec, Canada) has been cloned in the BamHI sites of pEGFP-C1
(CLONTECH Laboratories, Inc.). Sp100 (a gift from Dr. Maul, The
Wistar Institute, Philadelphia, PA) was also cloned in pEGFP-C1
(CLONTECH Laboratories, Inc.). The plasmid pCMX–green fluorescent
Figure 1. Colocalization by deconvolution immunofluorescence microscopy of CBP (NH2 terminus antibody; Santa Cruz Biotechnol-
ogy, Inc.) and Pml (5E10 antibody) proteins in SK-N-SH cells (A, F, K, and P) but not in 293 cells (B, G, L, and Q). Overexpression of
GFP–Pml in 293 cells (C and H) allows proper targeting into PML bodies (C) and concentrates CBP in PML bodies (M and R). Over-
expression of GFP–Sp100 in 293 cells (D and I) does not concentrate CBP in PML bodies (N and S). Overexpression of GFP–CBP in
293 cells (E and J) targets this protein to PML bodies (O and T). Bar, 5 mm. 
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protein (GFP)–PML (a gift from Dr. Evans, The Salk Institute for Biolog-
ical Studies, La Jolla, CA) has been described elsewhere (Kakizuka et al.,
1991). For transient transfection, 2 
 
m
 
g of DNA was diluted in 100 
 
m
 
l of
OptiMEM (GIBCO BRL), and 5 
 
m
 
l of Lipofectamine 2000 (GIBCO
BRL) was also diluted in 100 
 
m
 
l of OptiMEM. After 5 min at room tem-
perature, the two solutions were mixed and incubated for 20 min to allow
complex formation. The mixture was then directly added to the 2 ml of an-
tibiotic-free medium on the cells plated on glass coverslips. The medium
was changed 5 h after addition of the transfection mixture, and the cells
were allowed to grow for 24 h before fixation.
 
Interferon Induction
 
Human 293 cells were grown on coverslips and exposed to human 
 
a
 
-inter-
feron (Schering) by addition to the medium at a concentration of 1,000
U/ml (Lavau et al., 1995). After 72 h, the cells were fixed and labeled for
immunofluorescence microscopy.
 
Live Cell Imaging
 
Coverslips were placed on glass slides containing several drops of me-
dium surrounded by vacuum grease. The vacuum grease allows an air-
tight seal to form. Cells are capable of growing in these conditions for
 
.
 
24 h at 22
 
8
 
C. Individual cells were located by direct viewing through
the microscope eyepieces. For FRAP, the laser scanning microscope
(LSM 510; ZEISS) was set to laser scanning mode, and the initial imag-
ing conditions were determined. A 25 
 
3
 
 0.8 NA lens was used for these
experiments, and pixel sampling was set between 90 and 120 nm per
pixel. The argon laser spectral line at a wavelength of 488 nm was set to
an intensity of 
 
#
 
1.25% of its total power (15 mW) for image collection.
A region of interest, such as half of the cell nucleus, was defined, and the
software provided with the microscope provided the means to pho-
tobleach only this region, using 100 iterations at 25% laser intensity. 12-
bit images were collected before, immediately following, and at defined
intervals after bleaching. Since significant changes in green fluorescent
protein (GFP) signal equilibrium were not observed after 15 min, our to-
tal experiment time was set to 900 s to ensure that we observed complete
recovery of photobleaching.
 
Results
 
CBP Presence in PML Nuclear Bodies Depends on the 
Cell Line
 
The transcription coactivator CBP is a component of all
PML nuclear bodies in HEp-2 (LaMorte et al., 1998), SK-
N-SH, COS-1, and CHO cells as detected by immunofluo-
rescence microscopy (Boisvert et al., 2000; Fig. 1, A, F, K,
and P; data not shown). However, we have found that not
all cell lines exhibit this property. For example, HeLa, 293,
HS-68, and Hep-G2 (Fig. 1 Q; data not shown) cells do not
accumulate CBP in PML nuclear bodies. To determine the
 
subnuclear distribution of overexpression of the GFP–
CBP fusion protein, 293 cells were transiently transfected
with an expression construct coding for this protein. This
fusion protein has histone acetyltransferase activity, since
the levels of histone H3 and H4 acetylation detected by
immunofluorescence rise in proportion to the levels of
GFP–CBP overexpression (not shown). This indicates that
the GFP tag does not interfere with at least some of CBP’s
protein–protein interactions. The fusion protein is tar-
geted to PML nuclear bodies as well as being distributed
throughout the nucleoplasm (Fig. 1 J). These cells do not
normally concentrate CBP in PML nuclear bodies. Fur-
thermore, expression of GFP–Pml (Fig. 1, C, H, M, and R)
also leads to the accumulation of the endogenous CBP in
PML nuclear bodies of these cells (293) (Fig. 1 R). How-
ever, overexpression of Sp100 does not bring the endoge-
nous CBP into PML nuclear bodies (Fig. 1, D, I, N, and S).
This shows that the presence of CBP within PML nuclear
bodies depends on Pml but not Sp100. Interestingly, ex-
pression of Sp100 and Pml increases the number of PML
nuclear bodies (Fig. 1, H and I), whereas expression of
CBP does not. This indicates that Pml and Sp100, but not
CBP, participate in the formation of this nuclear structure.
The observation that CBP is a component of PML nu-
clear bodies in some cell lines, or that it can be forced to
accumulate in PML nuclear bodies with even low levels of
overexpression of Pml or CBP itself, indicates that CBP
may transit through PML nuclear bodies and accumulate
there if the conditions are favorable. Therefore, the
steady-state levels of CBP in PML nuclear bodies could be
shifted by slight changes in concentration of factors with
which CBP interacts.
 
Effect of Interferon on CBP Accumulation in
PML Bodies
 
Overexpression of Pml protein leads to an accumulation
of CBP in PML bodies in cells that do not otherwise
show this localization. We wished to determine whether
induction of Pml by 
 
a
 
-interferon might also lead to an
accumulation of CBP in PML bodies. As expected, after
induction of 293 cells with 
 
a
 
-interferon, the number of
PML bodies increased by three- to fourfold and the total
immunofluorescence signal increased approximately
threefold (not shown), consistent with previous studies
(Lavau et al., 1995). After 72 h of exposure to interferon,
Figure 2. Localization of  Pml
and CBP by deconvolution im-
munofluorescence microscopy
after exposure of these 293 cells
to a-interferon (1,000 U/ml) for
72 h. Bar: (left panel) 5.5 mm;
(right, panels 1–3) 1.38 mm. 
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the CBP distribution changed significantly. Before in-
duction of 293 cells, CBP is distributed in hundreds of
small foci throughout the nucleoplasm. There is almost
no overlap of these foci with PML bodies. However, af-
ter treatment larger foci appear, and many of these colo-
calize with PML bodies (Fig. 2, objects 1 and 2 in left
panel). Other accumulations of CBP, however, are near
but do not align precisely with PML bodies (Fig. 2, ob-
jects 2 and 3 in right panel). We do not know the basis
for the accumulation of CBP into the larger foci that are
not PML bodies upon interferon induction, but the accu-
mulation of CBP in PML bodies mimics the accumula-
tion seen when Pml levels are increased through tran-
sient overexpression.
Figure 3. FRAP of half-nucleus
of 293 cells expressing GFP–Pml
(A), GFP–Sp100 (B), or GFP–
CBP (C). Cells were imaged be-
fore the bleaching (Pre-
Bleached), immediately after
the bleaching (Bleached, time 5
0 s), and during fluorescence re-
covery at the indicated times. A
box indicates the area bleached,
corresponding to half the nu-
cleus. The fluorescence inten-
sity in the bleached and the un-
bleached regions was measured
and expressed as a relative in-
tensity where a value of one is
equal intensity in both halves.
The relative intensity over time
is shown. Fluorescence recovery
curves for CBP (D), Pml (E),
and Sp100 (F) show the kinetics
of redistribution of the differ-
ent  fluorescent proteins after
bleaching. As a control, recovery
of GFP alone was measured (G). 
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FRAP Analysis of GFP–CBP Movement
 
To determine whether CBP is a mobile molecule in the
nucleus and moves in or out of PML nuclear bodies, we
measured its mobility using the FRAP technique. The ap-
proach uses a high intensity laser from a laser scanning mi-
croscope to irreversibly bleach a region in the nucleus of a
cell expressing a GFP fusion protein (boxes in Fig. 3 repre-
sent the bleached region). After photobleaching, the cell is
imaged at different times to follow the redistribution of
the unbleached GFP fusion proteins. Because the bleach-
ing process irreversibly eliminates fluorescence of the
GFP without affecting the rest of the protein, it is possible
to visualize the normal movement of the unbleached pro-
tein in the cell. The recovery of the fluorescence is a mea-
sure for the mobility of the protein.
A region corresponding to approximately half of the cell
nucleus was photobleached (Fig. 3 C). After 40 and 80 s, a
wave of recovery of fluorescence can be seen to move
across the nucleus from the unbleached to the bleached
side and where the redistributed fluorescence is 
 
z
 
50% of
that before photobleaching. Plots of the gray values up to
200 s also show this directional wave, though the effect is
not apparent in the images after 80 s due to the limited gray
value resolution in the images (Fig. 3 C). Transient expres-
sion of GFP–CBP shows two different populations, one
that is concentrated in PML nuclear bodies and one that is
dispersed throughout the nucleus (Fig. 1 J and Fig. 3 C).
The GFP–CBP observed outside of PML nuclear bodies,
dispersed throughout the nucleoplasm, moves 
 
.
 
50 times
slower than GFP alone (Fig. 3, E and G). This difference in
mobility is likely not a consequence of the size of the pro-
tein, but rather due to interaction with other nuclear com-
ponents since some large structures (500 nm in diameter)
can move very rapidly through the nucleoplasm (Seksek et
al., 1997; Kruhlak et al., 2000). Fluorescence recovery of
these proteins is significantly faster than GFP–histone
H2B, which is immobile over very long periods of time (4 h)
(Phair and Misteli, 2000; our unpublished observations).
A time period of 7.5 min was necessary for the GFP–CBP
signal to reach equilibrium with the bleached half of the nu-
cleus compared with only 14 s for the GFP protein alone.
The half-recovery time was calculated to be 92 and 1.8 s, re-
spectively, for GFP–CBP and GFP alone. There is no ap-
parent difference in rates of recovery between CBP in
PML nuclear bodies and the CBP population that is dis-
persed throughout the nucleoplasm (Fig. 3 C). This means
that high-affinity binding sites for CBP exist in PML nu-
clear bodies and throughout the nucleoplasm. In control
experiments in which the entire nuclear fluorescence was
bleached, recovery was not observed over long time peri-
ods (30 min), indicating that de novo synthesis, import of a
cytoplasmic pool, or refolding of the GFP molecule did not
contribute significantly to fluorescence recovery (data not
shown). Moreover, cells can be bleached several times and
will still show similar kinetics of recovery, indicating that
there is no immediate damage induced by scanning the cell
using high intensity 488-nm-wavelength light. Photobleach-
ing does not affect the cell’s ability to enter mitosis and
does not affect the mobility of organelles or subnuclear do-
mains as visualized by differential interference optics. We
have also shown that paraformaldehyde-fixed cells show no
recovery after photobleaching.
 
CBP Moves In and Out of PML Nuclear Bodies
 
The rate of fluorescence recovery of CBP in PML nuclear
bodies is equivalent to that found in the nucleoplasm. To
Figure 3 (continued) 
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determine whether the direction of CBP movement is only
into PML nuclear bodies or is bidirectional into and out of
these domains, we performed both FRAP and fluores-
cence loss in photobleaching (FLIP) experiments. To de-
termine the rate of movement from the nucleoplasm into
PML nuclear bodies, we bleached an entire PML nuclear
body in a cell expressing GFP–CBP (Fig. 4, A–C). Com-
plete fluorescence recovery of the PML nuclear body was
observed after 5 s. This indicates that CBP can move rap-
idly from the nucleoplasm into PML nuclear bodies. To
determine whether CBP can leave the PML nuclear body,
we bleached a region just outside the domain to see
whether we could drain some fluorescence from it (FLIP)
(Fig. 4, D and E). Indeed, we observed a loss of fluores-
cence from the PML nuclear body followed by a quick re-
equilibration (5 s) of the fluorescence. The integrated in-
tensity of signal from the PML body shown in Fig. 4 E
decreased from 180 to 131 (gray values) after bleaching
but rebounded to 160 within 5 s. Our interpretation is that
fluorescent molecules that moved from the PML body to
the bleached region outside were rapidly replaced (5 s) by
fluorescent molecules moving into the PML body from un-
bleached but nearby regions of the nucleoplasm. There-
fore, we conclude that the movement of GFP–CBP be-
tween the nucleoplasm and the PML nuclear bodies is
bidirectional. The movement cannot be described as freely
mobile since it is significantly slower than that seen for a
freely diffusing molecule such as GFP (Fig. 3 G). These
experiments indicate that CBP in PML nuclear bodies is
not an insoluble aggregation of molecules which form by
random clustering of diffusing molecules. The bidirec-
tional movement further demonstrates that CBP mole-
cules are not recruited to these domains, stored, and then
degraded (Maul, 1998).
 
FRAP Analysis of GFP–PML and
GFP-Sp100 Movement
 
In contrast to the rate of movement of GFP–CBP in live
cells, GFP–Pml (Fig. 3, A and E) and GFP-Sp100 (Fig. 3, B
and F) fluorescence recovery occurred over much longer
times with very little recovery even after 10 min. The recov-
ery times are extremely long, indicating that these mole-
cules are immobile. This indicates that Pml and Sp100 are
not local concentrations of protein that form through sto-
chastic aggregation events from freely diffusing molecules.
Instead, the dynamic properties of Sp100 and Pml are con-
sistent with structural proteins that contribute to the integ-
rity of the PML nuclear body, which we propose is a special-
ized component of the protein-based nuclear architecture.
 
Sp100 and PML Are Immobile inside the PML
Nuclear Bodies
 
We wished to determine whether Sp100 and Pml could be
distinguished from CBP on the basis of mobility within the
PML nuclear body itself. To determine whether GFP-
Sp100 is moving within the PML nuclear body, we per-
formed FRAP at high resolution, bleaching a line passing
through the middle of a single PML nuclear body (Fig. 5
A). We found that the fluorescence within the PML nu-
clear body only recovers after relatively long periods (4
min). The same result was obtained for Pml within PML
nuclear bodies (data not shown). In contrast, GFP–CBP
(Fig. 5 B) fluorescence recovers rapidly from such a treat-
ment, making it difficult to observe the bleached line inside
the PML nuclear body in the first image recorded after the
bleaching step. After 5 s, the fluorescence of GFP–CBP has
been completely redistributed throughout the PML nuclear
bodies. The rate of redistribution is greater than that ob-
served when a half nucleus is bleached because the distance
the proteins have to travel is comparatively much less.
Again, the lack of movement of Sp100 and Pml within the
PML nuclear bodies lead us to conclude that they play a
structural role in these domains and that the steady-state
accumulations of Sp100 and Pml are very stable.
 
Discussion
 
We have shown previously that a protein-based nuclear
architecture exists in the eukaryotic nucleus under native,
nondisruptive conditions (Hendzel et al., 1999). The PML
Figure 4. Determination of the
direction of movement of GFP–
CBP. A whole PML nuclear
body was bleached (B, box) in a
293 cell expressing GFP–CBP. 5 s
after bleaching, an image show-
ing the fluorescence recovery
was recorded (5 s; C). A region
just outside the PML nuclear
body was then bleached (E,
box), indicating that fluores-
cence can be drained from the
PML nuclear body (E), which is
followed by a rapid reequilibra-
tion (5 s; F) of the fluorescence.
Bleached box in Fig. 4 B is 400
nm in length. 
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nuclear body represents a specialization of the protein-
based architecture and exists as an entity that is indepen-
dent of either DNA or RNA (Boisvert et al., 2000). Sev-
eral different proteins have the potential to localize to
varying degrees within these subnuclear domains, includ-
ing Pml and Sp100, which are consistently found there.
CBP, on the other hand, is concentrated in PML nuclear
bodies only under certain conditions. For example, there
are several cell lines where immunofluorescence micros-
copy cannot detect an accumulation of CBP in these do-
mains. However, even the lowest levels of overexpression
of Pml (where the size and number of PML bodies are un-
affected) or CBP above the endogenous levels in these
cells can lead to an accumulation of CBP in these bodies.
A similar effect is observed when endogenous Pml levels
are increased through 
 
a
 
-interferon induction. Thus, it ap-
pears that one function of Pml is to target CBP to PML
nuclear bodies. One model for the formation of such pro-
tein enrichments in the nucleoplasm is that rapidly diffus-
ing molecules can associate with and dissociate from bind-
ing sites within subnuclear domains (Phair and Misteli,
2000). This model may accurately apply to the formation
of some subnuclear domains but apparently does not ap-
ply to all of the components of PML nuclear bodies. At
least two components, Pml itself and Sp100, are relatively
immobile proteins in the nucleoplasm. They represent nu-
clear proteins that are tightly bound and do not move sig-
nificantly even within individual PML bodies. In contrast,
CBP moves relatively rapidly into and out of these do-
mains, behaving more similarly to the alternate splicing
factor in relation to nuclear speckles (Kruhlak et al. 2000;
Phair and Misteli, 2000). Though CBP’s movement is rela-
tively rapid compared with Pml, it is not freely mobile be-
cause it moves significantly slower than GFP, a protein
that does not bind specifically to any subnuclear com-
plexes. Therefore, there appear to be sites throughout the
nucleoplasm with which CBP can interact but discrete do-
mains where the equilibrium is such that local accumula-
tion is maintained. The number of these domains as well as
their size and shape can be modulated by stresses such as
heat shock, interferons, and viral infections. An alterna-
tive explanation for the apparent slower movement of
CBP is that it is part of a large complex that has a lower
diffusion constant. We think that this explanation is un-
likely because we have observed very large structures (up
to 500 nm in diameter) that can move very rapidly through
the nucleoplasm (Kruhlak et al., 2000).
We propose that Pml acts as an anchor for concentrating
factors such as CBP, thus providing a protein-based rather
than DNA-based affinity site able to concentrate CBP in
local nuclear volumes. The local accumulation of CBP, a
transcriptional coactivator and histone acetyltransferase,
may create a domain on the periphery of PML nuclear
bodies that is enriched in acetylated and transcriptionally
active chromatin. Indeed, we have observed that the chro-
matin surrounding PML nuclear bodies is highly acety-
lated, and nascent RNA is associated with the periphery of
these domains (Boisvert et al., 2000). We propose that
CBP accumulates in regions where a greater concentration
is required. Disruption of nuclear bodies, and thereby dis-
ruption of the levels of CBP and other PML body compo-
nents in certain subnuclear volumes, may influence the
level of activity of the surrounding genes. Hence, bio-
chemical alteration of the domain, by altering composition
or physical integrity, may lead to aberrant gene regulation
and a transformed phenotype (Zhong et al., 2000).
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Figure 5. FRAP of subregions
of PML bodies. A line of pho-
tobleaching through the middle
of one PML nuclear body
(boxes) was created in 293 cells
expressing GFP-Sp100 (A) and
GFP–CBP (B). After the
bleaching, images were re-
corded over time. Bleached
boxes are z300 nm in length. 
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